A Phase I/II Clinical Study Evaluating the Safety and Efficacy of KL003 Cell Injection in Transfusion-dependent β-thalassemia
This is a non-randomized, open label, single-dose study in up to 41 participants with β-thalassemia major. The goal of this clinical trial is to evaluate the safety and efficacy of KL003 cell injection in subjects with β-thalassemia major.
100 Clinical Results associated with Kanglin Biotechnology (Qingdao) Co., Ltd.
0 Patents (Medical) associated with Kanglin Biotechnology (Qingdao) Co., Ltd.
100 Deals associated with Kanglin Biotechnology (Qingdao) Co., Ltd.
100 Translational Medicine associated with Kanglin Biotechnology (Qingdao) Co., Ltd.